Markets

Pre-Market Earnings Report for March 13, 2018 : HDS, DKS, GDS, DSW, EPZM, NRE, ATRS, MLNT, ARLZ, GNMX, TSQ, GLMD

The following companies are expected to report earnings prior to market open on 03/13/2018. Visit our Earnings Calendar for a full list of expected earnings releases.

HD Supply Holdings, Inc. ( HDS ) is reporting for the quarter ending January 31, 2018. The industrial services company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.44. This value represents a no change for the same quarter last year. HDS missed the consensus earnings per share in the 2nd calendar quarter of 2017 by -3.08%. The days to cover, as reported in the 2/28/2018 short interest update, increased 133.74% from previous report on 2/15/2018. Zacks Investment Research reports that the 2018 Price to Earnings ratio for HDS is 16.57 vs. an industry ratio of 14.80, implying that they will have a higher earnings growth than their competitors in the same industry.

Dick's Sporting Goods Inc ( DKS ) is reporting for the quarter ending January 31, 2018. The retail company's consensus earnings per share forecast from the 14 analysts that follow the stock is $1.20. This value represents a 9.09% decrease compared to the same quarter last year. DKS missed the consensus earnings per share in the 3rd calendar quarter of 2017 by -4%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for DKS is 10.64 vs. an industry ratio of 16.70.

GDS Holdings Limited ( GDS ) is reporting for the quarter ending December 31, 2017. The technology services company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.13. This value represents a 40.91% increase compared to the same quarter last year. GDS missed the consensus earnings per share in the 2nd calendar quarter of 2017 by -9.09%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for GDS is -62.72 vs. an industry ratio of 19.70.

DSW Inc. ( DSW ) is reporting for the quarter ending January 31, 2018. The retail (shoe) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.27. This value represents a 35.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for DSW is 13.53 vs. an industry ratio of 17.00.

Epizyme, Inc. ( EPZM ) is reporting for the quarter ending December 31, 2017. The biomedical (gene) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $-0.56. This value represents a 6.67% increase compared to the same quarter last year. In the past year EPZM has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 3.08%. The "days to cover" for this stock exceeds 20 days. Zacks Investment Research reports that the 2017 Price to Earnings ratio for EPZM is -8.12 vs. an industry ratio of -7.10.

NorthStar Realty Europe Corp. ( NRE ) is reporting for the quarter ending December 31, 2017. The reit company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.11. This value represents a 99.99% decrease compared to the same quarter last year. In the past year NRE and beat the expectations the other quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for NRE is 70.87 vs. an industry ratio of 15.70, implying that they will have a higher earnings growth than their competitors in the same industry.

Antares Pharma, Inc. ( ATRS ) is reporting for the quarter ending December 31, 2017. The medical/dental supplies company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.03. This value represents a no change for the same quarter last year. In the past year ATRS has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ATRS is -25.36 vs. an industry ratio of 18.90.

Melinta Therapeutics, Inc. ( MLNT ) is reporting for the quarter ending December 31, 2017. The drug company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.59. This value represents a 80.33% increase compared to the same quarter last year. MLNT missed the consensus earnings per share in the 4th calendar quarter of 2016 by -5.26%. The "days to cover" for this stock exceeds 13 days. Zacks Investment Research reports that the 2017 Price to Earnings ratio for MLNT is -2.68 vs. an industry ratio of -8.30, implying that they will have a higher earnings growth than their competitors in the same industry.

Aralez Pharmaceuticals Inc. ( ARLZ ) is reporting for the quarter ending December 31, 2017. The drug company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.34. This value represents a 8.11% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ARLZ is -1.31 vs. an industry ratio of -8.30, implying that they will have a higher earnings growth than their competitors in the same industry.

Aevi Genomic Medicine, Inc. ( GNMX ) is reporting for the quarter ending December 31, 2017. The medical company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.15. This value represents a 31.82% increase compared to the same quarter last year. GNMX missed the consensus earnings per share in the 1st calendar quarter of 2017 by -7.41%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for GNMX is -2.54 vs. an industry ratio of -22.20, implying that they will have a higher earnings growth than their competitors in the same industry.

Townsquare Media, Inc. ( TSQ ) is reporting for the quarter ending December 31, 2017. The broadcast (radio/tv) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.13. This value represents a 31.58% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for TSQ is 10.36 vs. an industry ratio of 12.20.

Galmed Pharmaceuticals Ltd. ( GLMD ) is reporting for the quarter ending December 31, 2017. The drug company's consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.23. This value represents a 42.50% increase compared to the same quarter last year. In the past year GLMD and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for GLMD is -6.86 vs. an industry ratio of -8.30, implying that they will have a higher earnings growth than their competitors in the same industry.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GDS TSQ EPZM GLMD HDS ATRS DKS

Other Topics

Earnings